[1] HANG’OMBE B M, NAKAMURA I, SAMUI K L, et al. Evidence of Yersinia pestis DNA from fleas in an endemic plague area of Zambia . BMC Res Notes,2012, 5(1): 72.

[2] COBBS C G, CHANSOLME D H. Plague . Dermatol Clin, 2004, 22(3): 303-312.

[3] ROLLINS S E, ROLLINS S M, RYAN E T. Yersinia pestis and the plague . Am J Clin Pathol, 2003, 119: 78-85.

[4] BEVINS S N, BAROCH J A, NOLTE D L, et al. Yersinia pestis: Examining wildlife plague surveillance in China and the USA . Integr Zool, 2012, 7(1): 99-109.

[5] LAZARUS A A, DECKER C F. Plague . Respir Care Clin N Am, 2004, 10(1): 83-98.

[6] WANG J Y, WEI D, WANG G Z. Research progress in plague vaccine . Prog in Microbiol Immunol(微生物学免疫学进展), 2011, 39(2): 60-64.

[7] QUENEE L E,CORNELIUS C A,CILETTI N A, et al. Yersinia pestis caf1 variants and the limits of plague vaccine protection . Infect Immun, 2008, 76(5): 2025-2036.

[8] CUI P. Research progress in plague vaccine . Progress in Veterinary Medicine(动物医学进展), 2009, 30(5): 84 -86.

[9] TITBALL R W, WILLIAMSON E D. Yersinia pestis (plague) vaccines . Expert Opin Biol Ther, 2004, 4(6): 965-973.

SUN W, ROLAND K L, CURTISS R 3rd. Developing live vaccines against plague . J Infect Dev Ctries, 2011, 5(9): 614-627.

QUENEE L E, SCHNEEWIND O. Plague vaccines and the molecular basis of immunity against Yersinia pestis . Hum Vaccin, 2009, 5(12):817-823.

CAO L,LIM T,JUN S,et al. Vulnerabilities in Yersinia pestis caf operon are unveiled by a Salmonella vector . PLoS One, 2012, 7(4):36283.

GROSFELD H, COHEN S, BINO T, et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen . Infect Immun, 2003, 71: 374-383.

DU Y, ROSQVIST R, FORSBERG A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis . Infect Immun, 2002, 70(3): 1453-1460.

LI B, DU C, ZHOU L, et al. Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients . Clin Vaccine Immunol, 2012, 19(2):228-234.

ODHI A,SHARMA R K,BATRA H V. Yersinia rLcrV and rYopB inhibits the activation of murine peritoneal macrophages vitro E . Immunol Lett, 2005, 99(2): 146 -152.

SUN W, CURTISS R 3rd. Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis . Microb Pathog, 2012, 53(5-6):198-206.

OVERHEIM K A, DEPAOLO R W, DEBORD K L, et al. LcrV plague vaccine with altered immunomodulatory properties . Infect Immun, 2005, 73(8): 5152-5159.

JIANG L X, YANG R F, YU S Y. Research on plague vaccine . Chin J Endemiol(中国地方病学杂志), 2004, 23 (3): 285 -287.

JIAO L, WANG B X. Current status and prospects of research on new plague vaccines . Int J Biol(国际生物制品学杂志), 2011, 34 (4): 200-203.

BENNER G E, ANDREWS G P, RUSSEL W, et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice . Infect Immun, 1999, 67: 1922-1928.

SUOMALAINEN M, HAIKO J, RAMU P, et al. Using every trick in the book: The Pla surface protease of Yersinia pestis . Adv Exp Med Biol, 2007, 603: 268-278.

FEODOROVA V A, DEVDARIANI Z L. Development, characterization and diagnostic application of monoclonal antibodies against Yersinia pestis fibrinolysin and coagulase . Med Microbiol, 2000, 49: 261-269.

VALLS SER N M, HAIKO J, D E GROOT P G, et al. Thrombin-activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis . J Thromb Haemost, 2010, 8(10): 2232-2240.

SEBBANE F, JARRETT C O, GARDER D, et al. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague . Proc Natl Acad Sci, 2006, 103(14): 5526-5530.

SIMON S, DEMEURE C, LAMOURETTE P, et al. Fast and simple detection of yersinia pestis applicable to field investigation of plague foci . PLoS One, 2013, 8(1):4947.

VERNATI G, EDWARDS W H, ROCKE T E, et al. Antigenic profiling of Yersinia pestis infection in the Wyoming coyote (Canis latrans) . J Wildl Dis, 2011, 47(1): 21-29.

WANG S, JOSHI S, MBOUDJEKA I, et al. Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice . Vaccine, 2008, 26(13): 1664-1674.

ZHANG Q W, QI Z Z, XIN Y Q, et al. Evaluation of immunization protection efficacy of plague subunit vaccine . Chin J Prev Med(中华预防医学杂志), 2009, 43(9):785-788.

FU L F, HAO Z Z, CHANG Y L, et al. Titer test for serum antibody in mice immunized by the plague subunit vaccine and potency testing of plague vaccine in guinea pigs . Int J Biol(国际生物制品学杂志), 2010, 33 (1): 1-5.

QUENEE L E, CILETTI N, BERUBE B, et al. Plague in Guinea pigs and its prevention by subunit vaccines . Am J Pathol, 2011, 178(4):1689-1700.

QI Z, ZHOU L, ZHANG Q, et al. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270. Vaccine, 2010, 28(6): 1655-1660.

WILLIAMSON E D, PACKER P J, WATERS E L, et al. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague . Vaccine, 2011, 29(29-30): 4771-4777.

POWELL B S, ANDREWS G P, ENAMA J T, et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague . Biotechnol Prog, 2005, 21(5): 1490-1510.

DEL P G, SANTI L. Andrianaivoarimanana V Plant-derived recombinant F1,V,and F1-V fusion antigens of Yersinia pestis activate human cells of the innate and adaptive immune system . Int J Immunopathol Pharmacol, 2009, 22(1): 133 -143.

RIGANO M M, MANNA C, GIULINI A. Plants as bio-factories for the production of subunit vaccines against bio-security-related bacteria and viruses . Vaccine, 2009, 27: 3463-3466.

ELVIN S J, EYLES J E, HOWARD K A, et al. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine . Vaccine, 2006, 24(20): 4433-4439.

FEODOROVA V A, CORBEL M J. Prospects for new plague vaccines . Expert Rev Vaccines, 2009, 8(12): 1721-1738.

YAMANAKA H, HOYT T, YANG X, et al. A parenteral DNA vaccine protects against pneumonic plague . Vaccine, 2010, 28(18):3219-3230.

WANG S, MBOUDJEKA I, GOGUEN J D. Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines . Vaccine, 2010, 28(8): 2011-2019.

WANG S, HEILMAN D, LIU F, et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague . Vaccine, 2004, 22: 3348-3357.

AMEMIYA K, MEYERS J L, ROGERS T E, et al. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague . Vaccine, 2009, 27(16): 2220-2229.